{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:55:57Z","timestamp":1791176157009,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T00:00:00Z","timestamp":1417132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T00:00:00Z","timestamp":1417132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1038\/cgt.2014.60","type":"journal-article","created":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T11:14:51Z","timestamp":1417173291000},"page":"532-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Type I IFN gene delivery suppresses regulatory T cells within tumors"],"prefix":"10.1038","volume":"21","author":[{"given":"H","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Narumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Heike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,28]]},"reference":[{"key":"BFcgt201460_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nri3133","volume":"12","author":"JM Gonzalez-Navajas","year":"2012","unstructured":"Gonzalez-Navajas JM, Lee J, David M, Raz E . Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12: 125\u2013135.","journal-title":"Nat Rev Immunol"},{"key":"BFcgt201460_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.biochi.2007.04.006","volume":"89","author":"M Ferrantini","year":"2007","unstructured":"Ferrantini M, Capone I, Belardelli F . Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89: 884\u2013893.","journal-title":"Biochimie"},{"key":"BFcgt201460_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3109\/08916930903510880","volume":"43","author":"P Rizza","year":"2010","unstructured":"Rizza P, Moretti F, Belardelli F . Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010; 43: 204\u2013209.","journal-title":"Autoimmunity"},{"key":"BFcgt201460_CR4","doi-asserted-by":"publisher","first-page":"217ra3","DOI":"10.1126\/scitranslmed.3006353","volume":"6","author":"G Escobar","year":"2014","unstructured":"Escobar G, Moi D, Ranghetti A, Ozkal-Baydin P, Squadrito ML, Kajaste-Rudnitski A et al. Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. Sci Transl Med 2014; 6: 217ra3.","journal-title":"Sci Transl Med"},{"key":"BFcgt201460_CR5","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/j.1349-7006.2010.01578.x","volume":"101","author":"K Narumi","year":"2010","unstructured":"Narumi K, Kondoh A, Udagawa T, Hara H, Goto N, Ikarashi Y et al. Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer. Cancer Sci 2010; 101: 1686\u20131694.","journal-title":"Cancer Sci"},{"key":"BFcgt201460_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/sj.bjc.6602713","volume":"93","author":"M Ohashi","year":"2005","unstructured":"Ohashi M, Yoshida K, Kushida M, Miura Y, Ohnami S, Ikarashi Y et al. Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. Bri J Cancer 2005; 93: 441\u2013449.","journal-title":"Bri J Cancer"},{"key":"BFcgt201460_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/jgm.602","volume":"6","author":"K Hatanaka","year":"2004","unstructured":"Hatanaka K, Suzuki K, Miura Y, Yoshida K, Ohnami S, Kitade Y et al. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 2004; 6: 1139\u20131148.","journal-title":"J Gene Med"},{"key":"BFcgt201460_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1349-7006.2007.00408.x","volume":"98","author":"H Hara","year":"2007","unstructured":"Hara H, Kobayashi A, Yoshida K, Ohashi M, Ohnami S, Uchida E et al. Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci 2007; 98: 455\u2013463.","journal-title":"Cancer Sci"},{"key":"BFcgt201460_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1089\/hum.2011.046","volume":"23","author":"T Udagawa","year":"2012","unstructured":"Udagawa T, Narumi K, Goto N, Aida K, Suzuki K, Ochiya T et al. Syngeneic hematopoietic stem cell transplantation enhances the antitumor immunity of intratumoral type I interferon gene transfer for sarcoma. Hum Gene Ther 2012; 23: 173\u2013186.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201460_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","volume":"13","author":"F Belardelli","year":"2002","unstructured":"Belardelli F, Ferrantini M, Proietti E, Kirkwood JM . Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 119\u2013134.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFcgt201460_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1517\/14740330903066726","volume":"8","author":"LM Burdick","year":"2009","unstructured":"Burdick LM, Somani N, Somani AK . Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 2009; 8: 459\u2013472.","journal-title":"Expert Opin Drug Saf"},{"key":"BFcgt201460_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-3-540-71029-5_14","volume":"188","author":"SM Santini","year":"2009","unstructured":"Santini SM, Lapenta C, Santodonato L, D'Agostino G, Belardelli F, Ferrantini M . IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb Exp Pharmacol 2009; 188: 295\u2013317.","journal-title":"Handb Exp Pharmacol"},{"key":"BFcgt201460_CR13","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1158\/1078-0432.CCR-06-2363","volume":"13","author":"N Kobayashi","year":"2007","unstructured":"Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902\u2013911.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201460_CR14","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S1470-2045(11)70155-3","volume":"13","author":"JF Jacobs","year":"2012","unstructured":"Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ . Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012; 13: e32\u2013e42.","journal-title":"Lancet Oncol"},{"key":"BFcgt201460_CR15","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-11-1156","volume":"71","author":"WL Byrne","year":"2011","unstructured":"Byrne WL, Mills KH, Lederer JA, O'Sullivan GC . Targeting regulatory T cells in cancer. Cancer Res 2011; 71: 6915\u20136920.","journal-title":"Cancer Res"},{"key":"BFcgt201460_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4049\/jimmunol.182.1.259","volume":"182","author":"G Lal","year":"2009","unstructured":"Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009; 182: 259\u2013273.","journal-title":"J Immunol"},{"key":"BFcgt201460_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2009.07.005","volume":"31","author":"H Cucak","year":"2009","unstructured":"Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson-Lindbom B . Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 2009; 31: 491\u2013501.","journal-title":"Immunity"},{"key":"BFcgt201460_CR18","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538\u201318543.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcgt201460_CR19","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.4049\/jimmunol.0902609","volume":"185","author":"JL Gnerlich","year":"2010","unstructured":"Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, Belt BA et al. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 2010; 185: 4063\u20134071.","journal-title":"J Immunol"},{"key":"BFcgt201460_CR20","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1182\/blood-2008-12-195354","volume":"113","author":"MD Sharma","year":"2009","unstructured":"Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009; 113: 6102\u20136111.","journal-title":"Blood"},{"key":"BFcgt201460_CR21","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1158\/0008-5472.CAN-12-3788","volume":"73","author":"N Bacher","year":"2013","unstructured":"Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R et al. Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res 2013; 73: 5647\u20135656.","journal-title":"Cancer Res"},{"key":"BFcgt201460_CR22","doi-asserted-by":"publisher","first-page":"e22763","DOI":"10.1371\/journal.pone.0022763","volume":"6","author":"N Bacher","year":"2011","unstructured":"Bacher N, Graulich E, Jonuleit H, Grabbe S, Steinbrink K . Interferon-alpha abrogates tolerance induction by human tolerogenic dendritic cells. PloS One 2011; 6: e22763.","journal-title":"PloS One"},{"key":"BFcgt201460_CR23","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.4049\/jimmunol.0900526","volume":"184","author":"L Pace","year":"2010","unstructured":"Pace L, Vitale S, Dettori B, Palombi C, La Sorsa V, Belardelli F et al. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol 2010; 184: 5969\u20135979.","journal-title":"J Immunol"},{"key":"BFcgt201460_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nri2295","volume":"8","author":"C Dong","year":"2008","unstructured":"Dong C . TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8: 337\u2013348.","journal-title":"Nat Rev Immunol"},{"key":"BFcgt201460_CR25","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"II Ivanov","year":"2006","unstructured":"Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121\u20131133.","journal-title":"Cell"},{"key":"BFcgt201460_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","volume":"28","author":"XO Yang","year":"2008","unstructured":"Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008; 28: 29\u201339.","journal-title":"Immunity"},{"key":"BFcgt201460_CR27","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.4049\/jimmunol.178.11.6725","volume":"178","author":"L Xu","year":"2007","unstructured":"Xu L, Kitani A, Fuss I, Strober W . Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 2007; 178: 6725\u20136729.","journal-title":"J Immunol"},{"key":"BFcgt201460_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.immuni.2008.05.007","volume":"29","author":"XO Yang","year":"2008","unstructured":"Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29: 44\u201356.","journal-title":"Immunity"},{"key":"BFcgt201460_CR29","doi-asserted-by":"publisher","first-page":"7112","DOI":"10.4049\/jimmunol.180.11.7112","volume":"180","author":"SG Zheng","year":"2008","unstructured":"Zheng SG, Wang J, Horwitz DA . Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 2008; 180: 7112\u20137116.","journal-title":"J Immunol"},{"key":"BFcgt201460_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2009.01.002","volume":"15","author":"J Bollrath","year":"2009","unstructured":"Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91\u2013102.","journal-title":"Cancer Cell"},{"key":"BFcgt201460_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2007.12.020","volume":"13","author":"S Grivennikov","year":"2008","unstructured":"Grivennikov S, Karin M . Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008; 13: 7\u20139.","journal-title":"Cancer Cell"},{"key":"BFcgt201460_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","volume":"15","author":"S Grivennikov","year":"2009","unstructured":"Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103\u2013113.","journal-title":"Cancer Cell"},{"key":"BFcgt201460_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.molmed.2007.12.007","volume":"14","author":"WE Naugler","year":"2008","unstructured":"Naugler WE, Karin M . The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109\u2013119.","journal-title":"Trends Mol Med"},{"key":"BFcgt201460_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ccr.2009.01.009","volume":"15","author":"J Bromberg","year":"2009","unstructured":"Bromberg J, Wang TC . Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79\u201380.","journal-title":"Cancer Cell"},{"key":"BFcgt201460_CR35","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","volume":"17","author":"MS Anglesio","year":"2011","unstructured":"Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011; 17: 2538\u20132548.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201460_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1158\/0008-5472.CAN-06-2941","volume":"67","author":"H Kulbe","year":"2007","unstructured":"Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007; 67: 585\u2013592.","journal-title":"Cancer Res"},{"key":"BFcgt201460_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/1535-7163.MCT-10-0502","volume":"10","author":"L Song","year":"2011","unstructured":"Song L, Rawal B, Nemeth JA, Haura EB . JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 2011; 10: 481\u2013494.","journal-title":"Mol Cancer Ther"},{"key":"BFcgt201460_CR38","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-10-1095","volume":"16","author":"Y Guo","year":"2010","unstructured":"Guo Y, Nemeth J, O'Brien C, Susa M, Liu X, Zhang Z et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res 2010; 16: 5759\u20135769.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201460_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clml.2012.12.010","volume":"13","author":"A Chari","year":"2013","unstructured":"Chari A, Pri-Chen H, Jagannath S . Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma. Clin Lymphoma Myeloma Leukemia 2013; 13: 333\u2013337.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"BFcgt201460_CR40","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","volume":"103","author":"JF Rossi","year":"2010","unstructured":"Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H et al. A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Bri J Cancer 2010; 103: 1154\u20131162.","journal-title":"Bri J Cancer"},{"key":"BFcgt201460_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2011.10.014","volume":"48","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone\/prednisone versus mitoxantrone\/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012; 48: 85\u201393.","journal-title":"Eur J Cancer"},{"key":"BFcgt201460_CR42","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.4049\/jimmunol.148.8.2622","volume":"148","author":"JJ Mule","year":"1992","unstructured":"Mule JJ, Custer MC, Travis WD, Rosenberg SA . Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 1992; 148: 2622\u20132629.","journal-title":"J Immunol"},{"key":"BFcgt201460_CR43","first-page":"6020","volume":"52","author":"CA Mullen","year":"1992","unstructured":"Mullen CA, Coale MM, Levy AT, Stetler-Stevenson WG, Liotta LA, Brandt S et al. Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res 1992; 52: 6020\u20136024.","journal-title":"Cancer Res"},{"key":"BFcgt201460_CR44","first-page":"3679","volume":"52","author":"A Porgador","year":"1992","unstructured":"Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52: 3679\u20133686.","journal-title":"Cancer Res"},{"key":"BFcgt201460_CR45","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1172\/JCI44952","volume":"121","author":"DT Fisher","year":"2011","unstructured":"Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest 2011; 121: 3846\u20133859.","journal-title":"J Clin Invest"},{"key":"BFcgt201460_CR46","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1084\/jem.20090207","volume":"206","author":"L Wang","year":"2009","unstructured":"Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H . IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206: 1457\u20131464.","journal-title":"J Exp Med"},{"key":"BFcgt201460_CR47","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","volume":"31","author":"N Martin-Orozco","year":"2009","unstructured":"Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009; 31: 787\u2013798.","journal-title":"Immunity"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201460","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T09:18:52Z","timestamp":1690708732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,28]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["BFcgt201460"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2014.60","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,28]]},"assertion":[{"value":"15 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}